COMP <GO>
NPCE vs BWAY // EV/EBITDA & P/E VALUATION
Neuropace Inc. (NASDAQ) VS. BrainsWay Ltd. (NASDAQ) • 15-METRIC TALLY: NPCE 0
— BWAY 2
■ METRIC PARITY
LAST: $13.01 (+0.62%) • MKT CAP: $446.6M
valuation
—
LAST: $11.93 (+4.93%) • MKT CAP: $478.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NPCE VS. BWAY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NPCE | BWAY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -23.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.54% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -16.30% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -21.50% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 25.10% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.3 | 40.9 | -1.63 | BWAY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $446.6M | $478.7M | -$32.2M | BWAY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NPCE REV | BWAY REV | NPCE GROSS % | BWAY GROSS % | NPCE FCF | BWAY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $100.0M | — | 77.2% | — | -$11.3M | — |
| FY 2024 | $79.9M | — | 73.9% | — | -$18.3M | — |
| FY 2023 | $65.4M | — | — | — | -$19.7M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NPCE // BETA —
BWAY // BETA —